OptimizeRx Corporation (OPRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OPRX SEC filings page.
OptimizeRx Corporation (OPRX) reported $98.7M in revenue over the twelve months to Jun 30, 2026, down 5.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a business moving from operating losses to profitable, cash-generative growth while reducing debt and required reinvestment.
The turnaround is higher quality than earnings alone suggest: operating cash flow was$18.7M against net income of$5.1M , with the supplied cash-to-profit measure at364.7% . Free cash flow nearly matched operating cash flow as capital expenditures consumed just0.3% of operating cash flow, indicating little reported reinvestment was needed to produce that cash.
Revenue grew
Long-term debt fell
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of OptimizeRx Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
OptimizeRx Corporation has an operating margin of 10.7%, meaning the company retains $11 of operating profit per $100 of revenue. Among its peers this margin ranks in the lower range, for a profitability score of 23/100. This is up from -14.9% the prior year.
OptimizeRx Corporation's revenue surged 18.8% year-over-year to $109.4M, reflecting rapid business expansion. This strong growth earns a score of 85/100.
OptimizeRx Corporation carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.04, OptimizeRx Corporation holds $3.04 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.
OptimizeRx Corporation has a free cash flow margin of 17.1%, earning a moderate score of 59/100. The company generates positive cash flow after capital investments, but with room for improvement.
OptimizeRx Corporation generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 26/100. This is up from -17.2% the prior year.
OptimizeRx Corporation scores 2.61, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $170.7M against total liabilities of $48.6M. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
OptimizeRx Corporation passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, OptimizeRx Corporation generates $3.65 in operating cash flow ($18.7M OCF vs $5.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
OptimizeRx Corporation earns $2.21 in operating income for every $1 of interest expense ($11.7M vs $5.3M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
OptimizeRx Corporation generated $20.5M in revenue in Q2 2026. This represents a decrease of 29.8% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.
OptimizeRx Corporation's EBITDA was $976K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 77.2% from the same quarter a year earlier. Against the prior quarter it is down 33.2%.
OptimizeRx Corporation reported a net loss of $703K in Q2 2026. This represents a decrease of 145.9% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
OptimizeRx Corporation earned -$0.04 per diluted share (EPS) in Q2 2026. This represents a decrease of 150.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
OptimizeRx Corporation generated $8.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 88.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
OptimizeRx Corporation held $24.1M in cash against $17.8M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
OptimizeRx Corporation's gross margin was 76.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 12.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.
OptimizeRx Corporation's operating margin was -0.4% in Q2 2026, reflecting core business profitability. This is down 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.
OptimizeRx Corporation's net profit margin was -3.4% in Q2 2026, showing the share of revenue converted to profit. This is down 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
OptimizeRx Corporation's quarterly ROE was -0.5% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.
Capital Allocation
OptimizeRx Corporation invested $3.3M in research and development in Q2 2026. This represents an increase of 5.9% from the same quarter a year earlier. Against the prior quarter it is down 3.8%.
OptimizeRx Corporation invested $35K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 250.0% from the same quarter a year earlier. Against the prior quarter it is up 66.7%.
Not reported for Q2 2026.
OPRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.5M-29.8% | $19.8M-9.5% | $32.2M-0.2% | $26.1M+22.3% | $29.2M+55.2% | $21.9M+11.4% | $32.3M+13.9% | $21.3M+30.5% |
| Cost of Revenue | $4.8M-54.4% | $4.9M-42.8% | $8.1M-20.9% | $8.6M+8.8% | $10.6M+48.6% | $8.6M+14.7% | $10.3M-2.2% | $7.9M+20.4% |
| Gross Profit | $15.7M-15.8% | $14.9M+11.9% | $24.1M+9.4% | $17.5M+30.3% | $18.6M+59.2% | $13.3M+9.3% | $22.0M+23.4% | $13.4M+37.2% |
| R&D Expenses | $3.3M+5.9% | $3.4M+4.6% | N/A | N/A | $3.1M | $3.3M | N/A | N/A |
| SG&A Expenses | $9.2M-5.6% | $8.2M-13.6% | N/A | $14.4M+7.2% | $9.8M-32.0% | $9.5M-41.0% | N/A | $13.4M+4.2% |
| Operating Income | -$88K-102.7% | $396Kn/m | $8.5M+134.9% | $2.0Mn/m | $3.2Mn/m | -$2.1Mn/m | $3.6Mn/m | -$8.6Mn/m |
| EBITDA | $976K-77.2% | $1.5Mn/m | $9.6M+103.4% | $3.1Mn/m | $4.3Mn/m | -$1.0Mn/m | $4.7Mn/m | -$7.5Mn/m |
| Interest Expense | $1.1M-29.7% | $1.2M-10.9% | $1.2M-20.6% | $1.2M-24.3% | $1.6M+4.9% | $1.3M-16.1% | $1.6M | $1.5M |
| Income Tax | -$393K-297.5% | -$149Kn/m | $2.4M+5.9% | $270Kn/m | $199Kn/m | -$1.1M-411.9% | $2.3M | -$817K |
| Net Income | -$703K-145.9% | -$495Kn/m | $5.0Mn/m | $779Kn/m | $1.5Mn/m | -$2.2Mn/m | -$78Kn/m | -$9.1Mn/m |
| EPS (Basic) | -$0.04-150.0% | -$0.03n/m | $0.27n/m | $0.04n/m | $0.08n/m | -$0.12n/m | $0.00n/m | -$0.50n/m |
| EPS (Diluted) | -$0.04-150.0% | -$0.03n/m | $0.26n/m | $0.04n/m | $0.08n/m | -$0.12n/m | $0.00n/m | -$0.50n/m |
| Diluted Shares (Avg) | 19M-1.2% | 19M+1.6% | N/A | 19M+6.2% | 19M+4.1% | 18M+1.7% | N/A | 18M+10.1% |
OPRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $164.3M-2.9% | $167.3M-0.3% | $176.9M+3.4% | $170.3M+3.1% | $169.3M-2.1% | $167.8M-4.9% | $171.2M-6.7% | $165.2M+33.3% |
| Current Assets | $54.1M+0.1% | $56.2M+8.6% | $64.7M+19.9% | $56.3M+20.1% | $54.1M+17.6% | $51.7M+6.9% | $54.0M-0.7% | $46.9M-46.3% |
| Cash & Equivalents | $24.1M+45.3% | $20.2M+21.7% | $23.4M+74.6% | $19.5M+21.0% | $16.6M+10.9% | $16.6M+9.2% | $13.4M-3.4% | $16.1M+62.5% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% |
| Accounts Receivable | $24.8M-26.0% | $32.0M-2.2% | $37.8M-1.2% | $32.2M+22.4% | $33.5M+36.7% | $32.7M+10.0% | $38.2M+5.4% | $26.3M+26.3% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Goodwill | $70.9M0.0% | $70.9M0.0% | $70.9M0.0% | $70.9M0.0% | $70.9M-9.6% | $70.9M-9.6% | $70.9M-9.6% | $70.9M+212.6% |
| Total Liabilities | $33.2M-33.5% | $37.7M-26.9% | $48.6M-10.2% | $48.1M-5.3% | $50.0M-3.6% | $51.5M-4.3% | $54.2M-4.7% | $50.7M+548.6% |
| Current Liabilities | $9.7M-53.9% | $10.5M-43.0% | $21.3M+14.0% | $18.5M+27.3% | $21.1M+40.8% | $18.4M+9.5% | $18.7M+4.3% | $14.5M+88.3% |
| Non-Current Liabilities | $23.5M-18.7% | $27.2M-18.0% | $27.4M-23.0% | $29.6M-18.3% | $28.9M-21.6% | $33.1M-10.6% | $35.5M-8.8% | $36.2M+29854.9% |
| Long-Term Debt | $17.8M-29.3% | $21.3M-26.9% | $21.4M-30.5% | $24.8M-25.5% | $25.1M-22.2% | $29.2M-9.9% | $30.8M-10.0% | $33.3M+573658.6% |
| Total Equity | $131.1M+9.9% | $129.6M+11.5% | $128.3M+9.7% | $122.3M+6.8% | $119.3M-1.4% | $116.3M-5.1% | $117.0M-7.6% | $114.5M-1.4% |
| Retained Earnings | -$80.4Mn/m | -$79.7Mn/m | -$79.2Mn/m | -$84.3Mn/m | -$85.0Mn/m | -$86.6Mn/m | -$84.4Mn/m | -$84.3Mn/m |
Not reported in any period shown, so not listed: Inventory.
OPRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.6M+88.8% | -$467K-112.1% | $7.1M+3479.8% | $3.2M+78.8% | $4.6M+483.2% | $3.9M+82.4% | $198Kn/m | $1.8M+21.6% |
| Depreciation & Amortization | $1.1M-0.9% | $1.1M-2.7% | $1.1M-1.5% | $1.1M-1.4% | $1.1M+0.1% | $1.1M+2.5% | $1.1M+8.8% | $1.1M+134.5% |
| Stock-Based Compensation | $2.2M+48.4% | $1.8M+17.3% | N/A | N/A | $1.5M | $1.6M-48.5% | N/A | N/A |
| Capital Expenditures | $35K+250.0% | $21K-22.2% | $11K-35.3% | $10K-44.4% | $10K-77.8% | $27K-15.6% | $17K+240.0% | $18K-46.2% |
| Free Cash Flow | $8.6M+88.4% | -$488K-112.7% | $7.1M+3809.9% | $3.2M+80.0% | $4.6M+517.5% | $3.8M+83.9% | $181Kn/m | $1.8M+23.2% |
| Investing Cash Flow | -$35Kn/m | -$21Kn/m | $206Kn/m | -$10Kn/m | -$44Kn/m | -$84Kn/m | -$120Kn/m | -$92Kn/m |
| Financing Cash Flow | -$4.7Mn/m | -$2.7Mn/m | -$3.4Mn/m | -$258Kn/m | -$4.5Mn/m | -$587Kn/m | -$2.8M-107.8% | -$532Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
OPRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.5%+12.7pp | 75.3%+14.4pp | 74.8%+6.6pp | 67.2%+4.1pp | 63.8%+1.6pp | 60.9%-1.1pp | 68.2%+5.3pp | 63.1%+3.1pp |
| Operating Margin | -0.4%-11.4pp | 2.0%+11.6pp | 26.5%+15.2pp | 7.9%+48.0pp | 11.0%+30.9pp | -9.6%+16.0pp | 11.3%+49.8pp | -40.2%-18.4pp |
| Net Margin | -3.4%-8.7pp | -2.5%+7.5pp | 15.6%+15.8pp | 3.0%+45.8pp | 5.3%+26.6pp | -10.0%+25.0pp | -0.2%+14.4pp | -42.8%-25.3pp |
| Return on Equity | -0.5%-1.8pp | -0.4%+1.5pp | 3.9%+4.0pp | 0.6%+8.6pp | 1.3%+4.6pp | -1.9%+3.7pp | -0.1%+3.2pp | -8.0%-5.5pp |
| Return on Assets | -0.4%-1.3pp | -0.3%+1.0pp | 2.8%+2.9pp | 0.5%+6.0pp | 0.9%+3.2pp | -1.3%+2.6pp | -0.1%+2.2pp | -5.5%-3.2pp |
| Current Ratio | 5.58+3.0x | 5.37+2.6x | 3.04+0.2x | 3.05-0.2x | 2.57-0.5x | 2.82-0.1x | 2.89-0.1x | 3.23-8.1x |
| Debt-to-Equity | 0.14-0.1x | 0.16-0.1x | 0.17-0.1x | 0.20-0.1x | 0.21-0.1x | 0.250.0x | 0.260.0x | 0.29+0.3x |
| Liabilities-to-Equity | 0.25-0.2x | 0.29-0.2x | 0.38-0.1x | 0.39-0.1x | 0.420.0x | 0.440.0x | 0.460.0x | 0.44+0.4x |
| Asset Turnover | 0.120.0x | 0.120.0x | 0.180.0x | 0.150.0x | 0.17+0.1x | 0.130.0x | 0.190.0x | 0.130.0x |
| FCF Margin | 41.8%+26.2pp | -2.5%-20.0pp | 21.9%+21.4pp | 12.3%+3.9pp | 15.6%+11.7pp | 17.5%+6.9pp | 0.6%+22.6pp | 8.3%-0.5pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| OptimizeRx Corporation OPRX | FY2025 | $109.4M | $5.1M | 4.7% | $170.7M | 60/100 |
| Spok Holdings, Inc SPOK | FY2025 | $139.7M | $15.9M | 11.4% | $213.6M | 53/100 |
| NRC Health NRC | FY2025 | $137.4M | $11.3M | 8.2% | $496.6M | 49/100 |
| Definitive Healthcare Corp. DH | FY2025 | $241.5M | -$138.9M | -57.5% | $115.3M | 39/100 |
| So-Young International Inc. SY | FY2025 | $217.8M | -$34.6M | -15.9% | $213.3M | 33/100 |
Where OptimizeRx Corporation Ranks
Frequently Asked Questions
What is OptimizeRx Corporation's annual revenue?
OptimizeRx Corporation (OPRX) reported $109.4M in total revenue for fiscal year 2025. This represents a 18.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is OptimizeRx Corporation's revenue growing?
OptimizeRx Corporation (OPRX) revenue grew by 18.8% year-over-year, from $92.1M to $109.4M in fiscal year 2025.
Is OptimizeRx Corporation profitable?
Yes, OptimizeRx Corporation (OPRX) reported a net income of $4.6M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $5.1M, with a net profit margin of 4.7%.
What is OptimizeRx Corporation's EBITDA?
OptimizeRx Corporation (OPRX) had EBITDA of $16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does OptimizeRx Corporation have?
As of fiscal year 2025, OptimizeRx Corporation (OPRX) had $23.4M in cash and equivalents against $21.4M in long-term debt.
What is OptimizeRx Corporation's gross margin?
OptimizeRx Corporation (OPRX) had a gross margin of 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is OptimizeRx Corporation's operating margin?
OptimizeRx Corporation (OPRX) had an operating margin of 10.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is OptimizeRx Corporation's net profit margin?
OptimizeRx Corporation (OPRX) had a net profit margin of 4.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is OptimizeRx Corporation's return on equity (ROE)?
OptimizeRx Corporation (OPRX) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is OptimizeRx Corporation's free cash flow?
OptimizeRx Corporation (OPRX) generated $18.7M in free cash flow during fiscal year 2025. This represents a 290.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OptimizeRx Corporation's operating cash flow?
OptimizeRx Corporation (OPRX) generated $18.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are OptimizeRx Corporation's total assets?
OptimizeRx Corporation (OPRX) had $176.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OptimizeRx Corporation's capital expenditures?
OptimizeRx Corporation (OPRX) invested $58K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is OptimizeRx Corporation's current ratio?
OptimizeRx Corporation (OPRX) had a current ratio of 3.04 as of fiscal year 2025, which is generally considered healthy.
What is OptimizeRx Corporation's debt-to-equity ratio?
OptimizeRx Corporation (OPRX) had a debt-to-equity ratio of 0.17 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is OptimizeRx Corporation's liabilities-to-equity ratio?
OptimizeRx Corporation (OPRX) had a liabilities-to-equity ratio of 0.38 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is OptimizeRx Corporation's return on assets (ROA)?
OptimizeRx Corporation (OPRX) had a return on assets of 2.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is OptimizeRx Corporation's P/E ratio?
OptimizeRx Corporation (OPRX) trades at 37.1x earnings, its market capitalization divided by $4.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $170.7M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OptimizeRx Corporation's price-to-sales ratio?
OptimizeRx Corporation (OPRX) trades at 1.7x sales, its market capitalization divided by $98.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $170.7M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OptimizeRx Corporation's Altman Z-Score?
OptimizeRx Corporation (OPRX) has an Altman Z-Score of 2.61, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is OptimizeRx Corporation's Piotroski F-Score?
OptimizeRx Corporation (OPRX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are OptimizeRx Corporation's earnings high quality?
OptimizeRx Corporation (OPRX) has an earnings quality ratio of 3.65x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can OptimizeRx Corporation cover its interest payments?
OptimizeRx Corporation (OPRX) has an interest coverage ratio of 2.21x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is OptimizeRx Corporation?
OptimizeRx Corporation (OPRX) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.